Upper Limb Hypertonia — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Hypertonicity, a clinical term for increased resistance to movement, is a common condition in the upper limbs of both children and adults who have suffered brain injuries due to cerebral palsy, stroke, or traumatic incidents. This condition stems from changes in neural excitability, spasticity, and alterations in the biomechanical properties of muscles and connective tissues. The hypertonicity in the affected upper limb and other effects of brain injury, such as muscle weakness and learned non-use, can lead to a diminished ability to perform controlled movements. These include reaching, grasping, manipulating, and releasing objects. While general patterns of altered upper limb movement and posturing are recognized post-brain injury, the combination of underlying impairments and resulting performance characteristics vary from person to person. The individual presentation of the upper limb is influenced by factors such as the cause, size, and location of the brain lesion and the distribution and severity of the Upper Motor Neuron Syndrome (UMNS) symptoms.
Thelansis’s “Upper Limb Hypertonia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Upper Limb Hypertonia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Upper Limb Hypertonia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Upper Limb Hypertonia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
